-
Venus Medtech Initiates Global Study with Venus Vitae TAVR System Implantations
•
Venus Medtech (Hangzhou) Inc., listed on the Hong Kong Stock Exchange as HKG: 2500, has reached a significant milestone with the implantation of its next-generation transcatheter aortic valve replacement (TAVR) system, Venus Vitae, in two patients as part of the global, multi-center pivotal SMART-ALIGN study. This prospective, randomized, interventional study…
-
Venus Medtech’s VenusP-Valve Receives Marketing Approval in Venezuela, Expanding Global Reach
•
Venus Medtech (Hangzhou) Inc., (HKG: 2500), a leading medical device company, has announced that it has received marketing approval for its VenusP-Valve, a transcatheter pulmonary valve replacement (TPVR) system, in Venezuela. This marks another significant milestone for the company, as VenusP-Valve is the first self-expanding TPVR product to be approved…
-
Venus Medtech Partners with Valgen Holding on DragonFly Valve System
•
China-based Venus Medtech (Hangzhou) Inc., (HKG: 2500), has entered into a strategic partnership with Valgen Holding Corporation concerning Valgen’s DragonFly transcatheter mitral valve clamp system (DF). The financial terms of the agreement have not been disclosed. Commercial Collaboration and Market ExpansionUpon obtaining market approval for the DragonFly system, the two…
